N/A N=30 Effect of Whole-body Photobiomodulation on Muscular Performance Enhancement.
Sports Performance · Injury Prevention · Muscle Damage
Primary: Measurement of Blood Levels of Creatine Phosphokinase (CK) — 287.8; 249.2; 289.2 U/L
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=20 Utilizing Holmium Laser for FURS Renal Stone Lithotripsy Comparing Stone Breaking vs. Stone Dusting Settings
Stone Clearance
Primary: Stone Clearance — 6; 6; 3; 4 Participants
N/A N=134 Records for Alcohol Care Enhancement
Alcohol Use Disorder (AUD)
Primary: Percent of New Alcohol Use Disorder (AUD) Diagnosis Episodes That Meet Criteria for AUD Treatment Engagement Among Patients With a New AUD Diagnosis Who Are Empaneled to…
Phase 2 N=13 TG4010 and Nivolumab in Patients With Lung Cancer
Recurrent Non-Small Cell Lung Carcinoma · Stage I Non-Small Cell Lung Cancer · Stage II Non-Small Cell Lung Cancer
Primary: ORR Defined as the Proportion of Patients Whose Best Overall Response (BOR) is Either Complete Response (CR) or Partial Response (PR) According to RECIST 1.1 — 0.083…
N/A N=148 Bioresorbable Glass Fiber Matrix in the Treatment of Diabetic Foot Ulcers
Diabetic Foot Ulcer · Ulcer Foot · Diabetic Foot
Primary: Complete Wound Healing — 32; 16; 32; 16 Participants — p=0.007
Phase 1 N=32 A Clinical Study to Evaluate the Safety of CS-1103 in Healthy Participants
Substance Use Disorders · Methamphetamine Abuse · Methamphetamine Intoxication
Primary: Number of Participants With Treatment-Emergent Adverse Events (AEs) — 1; 1; 2; 4 Participants
N/A N=36 A Study of LY8888AX in Participants Using a Connected Insulin Management Platform
Type 1 Diabetes · Type 2 Diabetes · Type 2 Diabetes Treated With Insulin
Primary: Number of Missed Bolus Doses (MBDs) Per Week — 2.3; 2.3 missed bolus dose per week
N/A N=21 Effects of Remote Ischemic Conditioning on Hand Use in Individuals With SCI and ALS
Spinal Cord Injuries · Amyotrophic Lateral Sclerosis
Primary: Percent Change of Electromyographic Responses After Remote Ischemic Conditioning (RIC) Plus Hand Isometric Exercise — 17.4; 22.2; -19.2; 79.7 change (%) from baseline
Phase 2 N=48 Stellate Ganglion Block for COVID-induced Parosmia
COVID-19-Induced Parosmia
Primary: Parosmia Olfactory Dysfunction Outcomes Rating — 9; 9; 14; 11 score on a scale 0-112
N/A N=15 Effect of Auricular Vagal Nerve Electrical Stimulation on Post-Treatment Lyme Disease Syndrome
Post-Treatment Lyme Disease Syndrome
Primary: Horowitz Lyme-Multiple Systemic Infectious Disease Syndrome Questionnaire — 50.5; 44.8; 33.8; 25.6 score on a scale — p=0.07
Early Phase 1 N=17 Characterization of Tissue-Specific Immune Responses to Bronchoscopic Instillation of Mycobacterial Antigens Into the Human Lung
Healthy · Latent Tuberculosis Infection (LTBI)
Primary: Median Difference in CD4 Cell Response to Intrabronchial Instillation of Tuberculin Purified Protein Derivative (PPD) — 5.26; 0.725; 29.9; 2.92 % Antigen Specific T…
Phase 2 N=366 Immunogenicity and Safety of BPZE1 Intranasal Pertussis Vaccine in Healthy School-age Children
Bordetella Pertussis, Whooping Cough
Primary: Geometric Mean Fold Rise (GMFR) of Mucosal Immunogenicity S-IgA Against Whole Cell Extract at Day 29 — 3.8; 3.5; 1.2 Fold Rise
Phase 2 N=385 A Study of Nivolumab Alone or Nivolumab Combination Therapy in Colon Cancer That Has Come Back or Has Spread
Microsatellite Unstable Colorectal Cancer · Microsatellite Stable Colorectal Cancer · Mismatch Repair Proficient Colorectal Cancer
Primary: Objective Response Rate (ORR) by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 Per Investigator Assessment — 40.5; 66.4; 71.1; 3.3 percentage of participants
Phase 2 N=66 Milrinone in Congenital Diaphragmatic Hernia
Congenital Diaphragmatic Hernia · Persistent Pulmonary Hypertension of the Newborn · Hypoxemic Respiratory Failure
Primary: Oxygenation Response — 4.2; 2.6 Change in Oxygenation Index
N/A N=155,963 Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM)- Amiloride vs Triamterene
Hypertension
Primary: Time to Dementia Onset — 12.6; 14.8; 20.9; 21.5 Incidence rate per 1000 person year